CliffBio
small molecule

TOBI PODHALER

TOBRAMYCIN

Loss of exclusivityNovember 2030latest FDA-listed patent expiry
CompanyVIATRIS SPECIALTY LLC

Drug detail

Brand nameTOBI PODHALER
Active ingredientTOBRAMYCIN
Strength28MG
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalMarch 2013
Marketing statusRX

Listed patents

PatentExpiresType
10207066November 2030product
8869794September 2028product

More from VIATRIS SPECIALTY LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TOBI PODHALER patent cliff — loss of exclusivity November 2030 | CliffBio